Impact of SGLT2 Inhibitors Use on Risk of Postoperative Acute Kidney Injury Following Metabolic and Bariatric Surgery: A Retrospective Study
Abstract
BACKGROUND: This study investigated whether preoperative use of sodium-glucose cotransporter 2 inhibitors (SGLT2is), known for their cardio-renal benefits in type 2 diabetes (T2DM), reduces postoperative acute kidney injury (AKI) after metabolic and bariatric surgery (MBS).
METHODS: The TriNetX research network was used to analyze propensity-matched patients with T2DM who underwent MBS between 2010 and 2024. We compared patients who received SGLT2is (discontinued ≥ 1 week before surgery) with those using other antidiabetic medications. The primary outcome was AKI within 30 days after surgery. Secondary outcomes included risks of mortality, intensive care unit (ICU) admission, acute myocardial infarction/stroke, eGFR decline to < 60 mL/min/1.73 m2, and ketoacidosis.
RESULTS: After matching, 4364 patients were included (n = 2182 for each group). The incidence of AKI was identical between the groups (1.88% in both, OR 1.00, 95% CI 0.65-1.55, P = 1.00). No significant differences were observed in mortality, ICU admission, acute myocardial infarction/stroke, eGFR decline to 1 year, SGLT2is use was significantly associated with a lower risk of eGFR decline to < 60 mL/min/1.73 m2 (17.7% vs. 21.2%; OR 0.80, 95% CI 0.65-0.97; P = 0.024).
CONCLUSIONS: Preoperative SGLT2is use in patients undergoing MBS is associated with a reduced risk of GFR decline in those with longer-duration diabetes, suggesting potential renoprotective benefits. No increased risk of adverse outcomes was observed…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 4,364 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.